3 case(s) found.
This is the first of a three-case series. In October 1988, members of the Board and CEO's (chief executive officers) of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put in the market RU 486, a pill that provokes abortion without use of surgical methods.
-
Reference 2886
-
Published 05 Jan 2005
-
Length 15 page(s)
-
Region Europe
This is the first of a three-case series. In October 1988, members of the Board and CEO's (chief executive officers) of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put in the market RU 486, a pill that provokes abortion without use of surgical methods.
This is a French translation of the case?. This is the first of a three-case series. In October 1988, members of the Board and CEO's (chief executive officers) of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put in the market RU 486, a pill that provokes abortion without use of surgical methods.
-
Reference 2886
-
Published 05 Jan 2005
-
Length 5 page(s)
-
Region Europe
This is a French translation of the case?. This is the first of a three-case series. In October 1988, members of the Board and CEO's (chief executive officers) of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put in the market RU 486, a pill that provokes abortion without use of surgical methods.
This is a French translation of the case?. This is the first of a three-case series. In October 1988, members of the Board and CEO's (chief executive officers) of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put in the market RU 486, a pill that provokes abortion without use of surgical methods.
-
Reference 2886
-
Published 01 Jul 2005
-
Length 14 page(s)
-
Region Europe
This is a French translation of the case?. This is the first of a three-case series. In October 1988, members of the Board and CEO's (chief executive officers) of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put in the market RU 486, a pill that provokes abortion without use of surgical methods.